WIBP-CorV
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
WIBP-CorV is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. The other is BBIBP-CorV.
Development[edit]
In April 2020, China approved clinical trials for a candidate COVID-19 vaccine developed by Sinopharm's Beijing Institute of Biological Products (BBIBP-CorV)[1] and the Wuhan Institute of Biological Products (WIBP-CorV).[2] Both vaccines are chemically-inactivated whole virus vaccines for COVID-19.
On August 13, the Wuhan Institute of Biological Products published interim results of its Phase I (96 adults) and Phase II (224 adults) clinical studies. The report noted the vaccine had a low rate of adverse reactions and demonstrated immunogenicity, but longer-term assessment of safety and efficacy would require Phase III trials.[2]
Sinopharm said WIBP-CorV efficacy is 72.51%, lower than the 79.34% efficacy of BBIBP-CorV. On February 25, China approved WIBP-CorV for general use.[3][4] On March 10, Cayetano Heredia University running the BBIBP-CorV and WIBP-CorV trials in Peru announced they were seeking to suspend and unblind participants in the WIBP-CorV trials for lower efficacy and offer the participants BBIBP-CorV instead, which was showing efficacy.[5]
Authorization[edit]
Full authorization
Emergency authorization |
According to New York Times, the WIBP-CorV is only approved for limited use in United Arab Emirates.[6]
References[edit]
- ^ Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, et al. (October 2020). "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial". The Lancet. Infectious Diseases. 21 (1): 39–51. doi:10.1016/s1473-3099(20)30831-8. PMC 7561304. PMID 33069281.
- ^ a b Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, et al. (September 2020). "Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials". JAMA. 324 (10): 951–960. doi:10.1001/jama.2020.15543. PMC 7426884. PMID 32789505.
- ^ Eddy, Melissa (2021-02-25). "As Infections Dip, Governors Across U.S. Start Easing Restrictions". The New York Times. ISSN 0362-4331. Retrieved 2021-03-30.
- ^ Staff, Reuters (2021-02-25). "China approves two more domestic COVID-19 vaccines for public use". Reuters. Retrieved 2021-03-30.
- ^ "COMUNICADO A LA OPINIÓN PÚBLICA". Universidad Peruana Cayetano Heredia. March 9, 2021.
- ^ Zimmer, Carl; Corum, Jonathan; Wee, Sui-Lee. "Coronavirus Vaccine Tracker". The New York Times. ISSN 0362-4331. Retrieved 2021-03-30.
External links[edit]
 |
Scholia has a profile for WIBP-CorV (Q106322660). |
